Nasdaq

Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter ...

- PARADIGM ™ program comprises two 12-week randomized, placebo-controlled studies (APPROACH and EMBRACE) and a long-term extension study (EXTEND) - - EXTEND: a Phase III Open Label Extension Study ...
Business Wire

Homeward Selected to Receive Award for up to $12 Million from ARPA-H’s PARADIGM Program

SAN FRANCISCO--(BUSINESS WIRE)--Homeward ®, a company committed to rearchitecting the delivery of health and care in partnership with communities everywhere, starting in rural America, today announced ...
Stockhouse

Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter ...

“Just three years after filing an Investigational New Drug application for CYB003, the initiation of our Phase 3 program is a truly significant and gratifying milestone,” said ...